US Markets
Home›US Markets›M&A & Deals›Tempus AI targets the market for personalized cancer t…
Tempus AI targets the market for personalized cancer therapies
WSJ Markets reports that Tempus AI is positioning itself to capture a portion of the personalized cancer therapy business being developed by Moderna and Merck.
The outlet says Tempus’s strategy centers on Personalis, which would play a key role in the race to build the infrastructure tied to this therapeutic pipeline.
According to WSJ Markets, the opportunity is framed as a “picks and shovels” type of play, reflecting expected demand around personalized cancer treatment development and associated tools.
← Newer storyJobs data could sway a shaky bond marketOlder story →Hedge funds unwind yen shorts as BOJ hawkishness lifts the yen